BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37821635)

  • 1. MDM2 amplification is rare in gastric cancer.
    Abdullazade S; Behrens HM; Krüger S; Haag J; Röcken C
    Virchows Arch; 2023 Dec; 483(6):795-807. PubMed ID: 37821635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
    Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
    Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
    Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
    Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
    Das K; Gunasegaran B; Tan IB; Deng N; Lim KH; Tan P
    Cancer Lett; 2014 Oct; 353(2):167-75. PubMed ID: 25086186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
    Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
    Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
    Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
    Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
    Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
    Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
    Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
    Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of MDM2 gene amplification by fluorescence in situ hybridization and its diagnostic value in low-grade osteosarcoma].
    Li L; Zhang M; Dong RF; Su YB; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):237-242. PubMed ID: 38433050
    [No Abstract]   [Full Text] [Related]  

  • 11. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.
    Tajiri R; Ooi A; Fujimura T; Dobashi Y; Oyama T; Nakamura R; Ikeda H
    Hum Pathol; 2014 Apr; 45(4):725-34. PubMed ID: 24491355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 dual-color in situ hybridization (DISH) aids the diagnosis of intimal sarcomas.
    Jimbo N; Komatsu M; Itoh T; Hirose T
    Cardiovasc Pathol; 2019; 43():107142. PubMed ID: 31442826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
    Brunelli M; Tafuri A; Cima L; Cerruto MA; Milella M; Zivi A; Buti S; Bersanelli M; Fornarini G; Vellone VG; Rebuzzi SE; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Alongi F; Munari E; Pappagallo G; Iacovelli R; Mosca A; Porta C; Martignoni G; Antonelli A
    J Clin Pathol; 2022 Jan; 75(1):39-44. PubMed ID: 33144356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 amplification in malignant peripheral nerve sheath tumors correlates with p53 protein expression.
    Wallander ML; Tripp S; Layfield LJ
    Arch Pathol Lab Med; 2012 Jan; 136(1):95-9. PubMed ID: 22208493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal stromal tumors: clinical significance of p53 expression, MDM2 amplification, and KIT mutation status.
    Wallander ML; Layfield LJ; Tripp SR; Schmidt RL
    Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):308-12. PubMed ID: 23060298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers.
    Forslund A; Zeng Z; Qin LX; Rosenberg S; Ndubuisi M; Pincas H; Gerald W; Notterman DA; Barany F; Paty PB
    Mol Cancer Res; 2008 Feb; 6(2):205-11. PubMed ID: 18314481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 gene amplification in esophageal carcinoma.
    Michalk M; Meinrath J; Künstlinger H; Koitzsch U; Drebber U; Merkelbach-Bruse S; Bollschweiler E; Kloth M; Hartmann W; Hölscher A; Quaas A; Grimminger PP; Odenthal M
    Oncol Rep; 2016 Apr; 35(4):2223-7. PubMed ID: 26796597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
    Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
    Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.
    Grünewald I; Trautmann M; Busch A; Bauer L; Huss S; Schweinshaupt P; Vollbrecht C; Odenthal M; Quaas A; Büttner R; Meyer MF; Beutner D; Hüttenbrink KB; Wardelmann E; Stenner M; Hartmann W
    Oncotarget; 2016 Nov; 7(46):75261-75272. PubMed ID: 27662657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of MDM2 RNA in situ hybridization for low-grade osteosarcoma: Consistency comparison of RNA in situ hybridization, fluorescence in situ hybridization, and immunohistochemistry.
    Chen C; He X; Chen M; Du T; Qin W; Jing W; Zhang H
    Virchows Arch; 2023 Jun; 482(6):999-1010. PubMed ID: 36977943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.